Name | Type | Posted | Actions |
|---|---|---|---|
RFI RRPV HIPE.pdf | Jun 17, 2026 |
High Performance Antigen Diagnostics
Contact and place of performance
ATI
Washington, DC
USA
“High Performance Antigen Diagnostics” Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.
The Office of the Assistant Secretary for Preparedness and Response (ASPR), through the Biomedical Advanced Research and Development Authority (BARDA) Division of Contracts Management and Acquisition, issued this Request for Information (RFI) regarding high-performance antigen diagnostics. Identified under solicitation number RRPV-HPAD, the notice seeks to assess the research, development, and product landscape for next-generation immunoassay technologies. The primary objective is to identify solutions suitable for near-patient settings that address the analytical sensitivity and multiplexing limitations inherent in conventional antigen-based tests, which currently restrict clinical utility during early infections or for syndromic panels compared to nucleic acid amplification tests.
This market research effort is classified under NAICS 541714 for Research and Development in Biotechnology (except Nanobiotechnology) and PSC AN13 for Health R&D Services; Health Care Services; Experimental Development. There is no set-aside designated for this requirement. Performance is centered in Washington, DC, and the inquiry is managed through the Rapid Response Partnership Vehicle (RRPV) with ATI listed as the point of contact.
The response deadline for this RFI is July 17, 2026. One supporting document, a PDF titled RFI RRPV HIPE.pdf, was included with the notice published on June 17, 2026. The information gathered through this process will assist the agency in understanding current capabilities for improving the speed, cost, and ease of use of high-performance immunoassays.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.